|1.||Shakir, Saad A W: 1 article (03/2010)|
|2.||Osborne, Vicki: 1 article (03/2010)|
|3.||Layton, Deborah: 1 article (03/2010)|
|4.||Hazell, Lorna: 1 article (03/2010)|
|5.||Spark, R F: 1 article (05/2005)|
|1.||Psychological Sexual Dysfunctions (Sexual Arousal Disorder)
03/01/2009 - "There is some suggestion of a link between sexual dysfunction in postmenopausal women and low circulating concentrations of testosterone.1 This underlies the development of a new transdermal testosterone patch (black triangle down Intrinsa - Procter & Gamble) that has recently been licensed in the UK for the treatment of women who have hypoactive sexual desire disorder (HSDD) following a menopause induced by surgery (i.e. "
03/01/2010 - "Intrinsa is a transdermal testosterone patch that is indicated for use in hypoactive sexual desire disorder (HSDD) in women who have undergone bilateral oophorectomy and hysterectomy (surgically-induced menopause) receiving concomitant oestrogen therapy. "
05/01/2005 - "The sexual medicine community watched with interest as the Food and Drug Administration (FDA) considered the Proctor & Gamble new drug application for Intrinsa (a testosterone patch for hypoactive sexual desire disorder for women who had undergone surgical castration via bilateral oophorectomy). "